Last spring, a rapid polymerase chain reaction (PCR) test for COVID-19—developed by Northwestern University spinoff company Minute Molecular Diagnostics—received emergency use authorization (EUA) status from the U.S. Food and Drug Administration (FDA). Now, the team behind this revolutionary test is adapting its platform to detect monkeypox.